Printer Friendly

Citycon to pay equity repayment of EUR0.0325 per share.

M2 EQUITYBITES-June 20, 2017-Citycon to pay equity repayment of EUR0.0325 per share

(C)2017 M2 COMMUNICATIONS http://www.m2.com

Citycon Oyj (HEX:CTY1S), an owner, developer and manager of urban grocery-anchored shopping centres in the Nordic and Baltic region, announced on Tuesday that its board of directors has decided that an equity repayment of EUR0.0325 per share be distributed from the invested unrestricted equity fund of the company, based on the authorisation by the Annual General Meeting 2017 held on 22 March 2017.

The company said a shareholder registered in the company's shareholders' register maintained by Euroclear Finland Ltd on the record date for the equity repayment 22 June 2017, will receive the equity repayment on 30 June 2017.

At Citycon's Annual General Meeting, a resolution was passed to authorise the board of directors to decide in its discretion on the distribution of dividend and equity repayment. With this authorisation, the total amount of the dividend to be distributed shall not exceed EUR0.01 per share and the maximum amount of equity repayment distributed from the invested unrestricted equity fund shall not exceed EUR0.12 per share. This authorisation is valid until the opening of the Annual General Meeting 2018.

Citycon Oyj added that it has distributed a total dividend and equity repayment of EUR0.065 per share during the year 2017, after the asset distribution on 30 June 2017. The remaining authorisation of Citycon's Board of Directors is EUR0.065 per share.

((Comments on this story may be sent to [email protected]))

COPYRIGHT 2017 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2017 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jun 20, 2017
Words:257
Previous Article:Evotec AG to make a strategic investment in Facio Therapies.
Next Article:Heptares Therapeutics plans to relocate to a new facility in Cambridge.
Topics:

Terms of use | Privacy policy | Copyright © 2025 Farlex, Inc. | Feedback | For webmasters |